Cross Country Healthcare Q4 net income drops 77% on 34% revenue decline

CROSS COUNTRY HEALTHCARE INC

2023-FY EPS reported $2.05 revenue$2,019,728,000

Q4 2023 revenue $414M, down 34% YoY and 6% sequentially; full year revenue $2.02B, down 28%.
Q4 net income $9.0M (-77% YoY); diluted EPS $0.26 vs $1.05 in Q4 2022.
Q4 adjusted EBITDA $20.6M (-64% YoY); margin 5.0%, down 410 bps YoY.
Q4 cash from ops $12.1M (+179% YoY); full year cash from ops $248.5M (+85% YoY).
Full year adjusted EPS $2.23 vs $5.27 in 2022; net income $72.6M (-61% YoY).

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CROSS COUNTRY HEALTHCARE INC reported financial results for full year ended December 31, 2023.

Period: full year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 21, 2024, Cross Country Healthcare, Inc. (“the Company”) issued a press release announcing results for the fourth quarter and full year ended December 31, 2023, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CROSS COUNTRY HEALTHCARE INC reported financial results for fourth quarter ended December 31, 2023.

Period: fourth quarter ended December 31, 2023
Result: reported results

Exact text from the filing

On February 21, 2024, Cross Country Healthcare, Inc. (“the Company”) issued a press release announcing results for the fourth quarter and full year ended December 31, 2023, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K.

View on SEC.gov

Browse all earnings releases →

CROSS COUNTRY HEALTHCARE INC filing history →

Source: SEC EDGAR

accession 0001628280-24-005913

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.